Dose modification consisted of giving interferon on alternating days as long as necessary to alleviate symptoms, and 25% dose reduction of DTIC in case of grade 3 or more haematological toxicity, or nausea.
Evaluation of toxicity followed the WHO guide lines (WHO Handbook, 1979 Of the 11 female patients, six responded, with three complete remissions. The 38% response rate (95% confidence level 20-59%) is not suggestive of a major impact on response from the addition of 5-FU, in the magnitude of triplication as suggested in the first reports on synergism between interferon and 5-FU (Wadler et al., 1989) . Previously, we reported a response rate of the two drugs of 35% (95% confidence 19-55%) (Mulder et al., 1990) . Also, in colon cancer the combined response rate of 5-FU and interferon is levelling off to a more modest synergism (Wadler et al., 1991) .
However, the absence of development of brain symptoms during treatment and in the follow-up of responders is striking in comparison to our previous experience, when 18 of 62 patients developed such symptoms (Mulder et al., 1989; Mulder et al., 1990) . This finding might confirm the observation of a response of cerebral melanoma localisation following 5-FU and interferon (Jacobs et al., 1989) . In the dose used here 5-FU has no important organ toxicity, although it might add to the fatigue induced by interferon. The 38% response rate also confirms the somewhat higher response rate of the combination of DTIC and interferon when compared to each drug separately (McClay & Mastrangelo, 1988; Creagan et al., 1987) .
Although the majority of responses is quite short, this study confirms that occasionally complete responses can be prolonged and very worthwhile, especially if they can be reached with relatively untoxic treatment. In that respect the toxicity profile of DTIC containing regimens has changed dramatically following the introduction of ondansetron as an antiemetic. Most of our patients considered the 5-FU infusion, without ondansetron prophylaxis, as the more toxic one in comparison to DTIC. In an interim report on this study (Mulder et al., 1991) , eight responses were seen in the first 12 patients, in the next 14 patients only two partial responses were seen. In our study, this difference coincided with the introduction of ondansetron, however a causal relation is unlikely. An important predictor of response seems to be sex, and more female patients were entered during the first part of the study.
